CORAL GABLES, FL / ACCESSWIRE / September 10, 2018 / Investors have been following the new trend that has presented itself within two industries finding strong crossovers recently. We're talking about companies within the Biotech and cannabis sectors. These are stocks that have rallied ahead of potential acquisitions, strategic investments, and even new licensing deals. Though marijuana isn't legal across all of North America, the push from the medical marijuana field has helped boost the appeal in many cases.
A number of companies are finding promise by taking a once taboo drug and expanding its uses in the medical space. With both THC and CBD being utilized for new applications, investors are not only looking at recreational but also biopharmaceutical stocks targeting the use of these compounds.
GTBiopharma (GTBP), for instance has been building a biopharmaceutical pipeline targeting everything from pain management to cancer treatments. The company's therapy that is furthest along in phase trials is its OXS-1550. This therapy targets cancer cells expressing the CD19 receptor and/or CD22 receptors, which includes B-cell leukemias and lymphomas and has a modified form of diphtheria toxin (DT390) as its cytotoxic drug payload. After OXS-1550 binds to cancer cells, it is taken in by the cancer cells and subsequently deploys its cytotoxic diphtheria toxin payload, which inhibits protein synthesis and kills the cancer cells.
Recent industry developments have put NK cell treatments in the spotlight. In a September release, the company's CEO Dr. Raymond Urbanski stated, "The recent collaboration, $96M upfront with $5B in milestone/royalty payments, announced on August 27th between Affimed and Roche/Genentech not only provides validation of the NK cell hypothesis but more specifically of the NK cell - engager concept. GT Biopharma, since its inception on September 1, 2017 has been diligently working, along with our colleagues at the Masonic Cancer Center, on bringing our TriKE and TetraKE NK cell-engager platforms into and through the regulatory pathway and into clinical development."
GT Biopharma previously announced the initiation of a combination trial of OXS-1550 and ibrutinib, which is a potent small molecule Bruton Tyrosine Kinase inhibitor and is already an established chemotherapeutic agent. GT Biopharma believes combination therapies like these that kill cancer cells based on entirely different mechanisms are the future of cancer treatment. The recent investment of nearly $100 million into another industry cohort alone may also suggest the same.
FSD Pharma (OTC PINK: FSDDF) (HUGE.CN) reported its financial and operational results for the second quarter of fiscal 2018, ended June 30th, 2018. According to its filings, the company maintained a balance sheet with cash of $31,700,000, no debt, and stronger asset holdings. FSD is said to be aiming for a total grow capacity in excess of 3,000,000 square feet. The company also is expecting an annual output of 400,000,000 grams of which FSD Pharma would benefit 200,000,000 grams.
FSD Pharma through its wholly owned subsidiary FV Pharma is a licensed producer of marijuana under the Access to Cannabis for Medical Purposes Regulations (ACMPR) having received its cultivation license on October 13, 2017. Headquartered at the former Kraft plant in Cobourg, Ontario, approximately an hour's drive from Toronto, FV Pharma management's mission is to transform the facility into the largest hydroponic indoor cannabis facility in the world.
Bellerophon Therapeutics, Inc. (BLPH) is another clinical-stage biotherapeutics company. Bellerophon focuses on developing innovative products combining novel drugs and devices in the treatment of cardiopulmonary diseases. Our mission is to develop well-studied molecules deployed through innovative delivery systems to treat diseases with significant unmet clinical need.
Last month the company announced that the Data Monitoring Committee (DMC) has completed its pre-specified interim analysis from the first 75 enrolled subjects completing 16-weeks of treatment in the Phase 3 INOvation-1 study evaluating INOpulse® for the treatment of pulmonary arterial hypertension (PAH).
In a corporate press release, Fabian Tenenbaum, Chief Executive Officer of Bellerophon Therapeutics said, "Over the next few weeks, we intend to further analyze the full data set available to us from this interim analysis in order to determine the next steps in our PAH program. On behalf of everyone at Bellerophon, I would like to thank all of the patients and physicians who participated in the INOvation-1 study."
Shares are up sharply during Monday's trading session.
MarijuanaStocks.com is the leading web destination for all things cannabis. Investors can find marijuana-related financial, medical, legal, and social news anytime day or night. Writers are invited to submit cannabis related articles for publication.
The growing number of clinical trials that are being conducted in immunotherapy is anticipated to fuel the growth of the cancer immunotherapy market. The market is segmented into colorectal cancer, lung cancer, breast cancer, melanoma, prostate cancer, and blood cancer. Based on therapy types, the market can be divided into immune system modulators, immune checkpoint inhibitors, immune checkpoint inhibitors, and monoclonal antibodies. Monoclonal antibodies method has a leading market share, while demand for immune checkpoint inhibitors is expected to increase rapidly.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. MAPH Enterprises LLC which owns www.MarijuanaStocks.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
MAPH Enterprises LLC, which owns www.MarijuanaStocks.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. MAPH Enterprises LLC, which owns www.MarijuanaStocks.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. Pursuant to an agreement between an affiliate of MAPH Enterprises, LLC, Midam Ventures LLC and GT Biopharma, Midam has been paid $200,000 from the company and ZERO shares of GT Biopharma Inc. for a duration beginning July 16, 2018 and ending August 16, 2018. Midam Ventures has been paid an additional $200k by GT Biopharma and has extended its marketing period through Sept 16, 2018. We may buy or sell additional shares of (GTBP) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.